← ANALYST RATINGS · TIPRANKS
Viridian Therapeutics (VRDN): analyst forecast and price target
Analyst consensus
Strong Buy9 Buy0 Hold0 Sell
Ratings of 9 analysts in the last 3 months · top analysts only12-month forecast
Based on 9 price targets given in the last 3 months, the average target is $32.71, the highest $41.00, the lowest $22.00. The average is +71.9% from the last price of $19.03.
Analyst ratings 17
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $19.00 → $20.50+7.9% | Hold | +7.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $19.00 → $20.50+7.9% | Hold | +7.7% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $18.50 → $20.00+8.1% | Hold | +5.1% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $18.00 → $19.00+5.6% | Hold | −0.2% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $19.00 → $20.00+5.3% | Hold | +5.1% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $18.00 → $19.50+8.3% | Hold | +2.5% | Reiterated | 17.10.26on TipRanks 00:06 | — | |
| Derek Archila★★★★★★★★★★#252 · hits 58% · avg +22.7% | Wells Fargo | $31.00 | Buy | +62.9% | Assigned | 14.10.26on TipRanks 06:50 | +2.0%next day +6.1% | ↗ |
| Lisa Walter★★★★★★★★★★#5591 · hits 50% · avg +3.0% | RBC Capital | $38.00 | Buy | +99.7% | Reiterated | 08.10.26on TipRanks 21:45 | +1.1%next day −1.9% · 5 days +4.0% | ↗ |
| Rami Katkhuda★★★★★★★★★★#297 · hits 55% · avg +31.7% | LifeSci Capital | $35.00 | Buy | +83.9% | Reiterated | 02.10.26on TipRanks 17:55 | −2.7%next day −4.7% · 5 days −4.1% | ↗ |
| Gregory Renza★★★★★★★★★★#373 · hits 55% · avg +18.8% | Truist Financial | — | Buy | — | Reiterated | 01.09.26on TipRanks 08:05 | +0.1%next day −1.5% · 5 days −1.4% | ↗ |
| Richard Law CFA★★★★★★★★★★#3237 · hits 50% · avg +9.1% | Goldman Sachs | $39.00 → $40.00+2.6% | Buy | +110.2% | Reiterated | 19.08.26on TipRanks Aug 20 09:35 | +3.4%next day −0.4% · 5 days −1.8% | ↗ |
| Alex Thompson CFA★★★★★★★★★★#60 · hits 73% · avg +50.6% | Stifel Nicolaus | $40.00 | Buy | +110.2% | Reiterated | 13.08.26on TipRanks 11:35 | −4.6%next day +0.6% · 5 days +13.4% | ↗ |
| Gavin Clark-Gartner★★★★★★★★★★#172 · hits 68% · avg +40.8% | Evercore ISI | $26.00 | Buy | +36.6% | Reiterated | 10.08.26on TipRanks 08:40 | −2.2%next day −0.1% · 5 days +0.2% | ↗ |
| Douglas Tsao★★★★★★★★★★#207 · hits 56% · avg +24.3% | H.C. Wainwright | $22.00 | Buy | +15.6% | Reiterated | 07.08.26on TipRanks Aug 6 16:46 | +4.2%next day −2.2% · 5 days −6.8% | ↗ |
| Joseph Thome★★★★★★★★★★#320 · hits 57% · avg +24.8% | TD Cowen | — | Buy | — | Reiterated | 06.08.26on TipRanks Aug 7 03:55 | +7.0%next day +4.2% · 5 days −3.5% | ↗ |
| Lachlan Hanbury Brown★★★★★★★★★★#11394 · hits 35% · avg −5.4% | William Blair | — | Buy | — | Reiterated | 06.08.26on TipRanks 15:15 | +7.0%next day +4.2% · 5 days −3.5% | ↗ |
| Serge Belanger★★★★★★★★★★#674 · hits 49% · avg +14.9% | Needham | $34.00 | Buy | +78.7% | Reiterated | 06.08.26on TipRanks 09:15 | +7.0%next day +4.2% · 5 days −3.5% | ↗ |
| Laura Chico★★★★★★★★★★#527 · hits 54% · avg +14.2% | Wedbush | $43.00 → $41.00−4.7% | Buy | +115.4% | Reiterated | 06.08.26on TipRanks Aug 4 17:15 | +1.3%next day +7.0% · 5 days +8.2% | ↗ |
| Faisal Khurshid★★★★★★★★★★#51 · hits 66% · avg +74.6% | Jefferies | $30.00 | Buy | +57.6% | Reiterated | 30.06.26on TipRanks 08:45 | −3.0%next day +0.7% · 5 days +8.3% | ↗ |
| Thomas Smith★★★★★★★★★★#45 · hits 57% · avg +51.1% | Leerink Partners | $50.00 | Buy | +162.7% | Reiterated | 06.04.26on TipRanks 13:25 | −26.7%next day +0.4% · 5 days +2.4% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $50.00 | Buy | +162.7% | Initiated | 07.01.26on TipRanks 20:25 | −0.8%next day +4.0% · 5 days +8.5% | ↗ |
| Julian Harrison★★★★★★★★★★#42 · hits 57% · avg +53.4% | BTIG | $61.00 | Buy | +220.5% | Reiterated | 04.11.25on TipRanks 07:00 | −1.4%next day +7.9% · 5 days +24.9% | ↗ |
| David Martin PhD★★★★★★★★★★#656 · hits 53% · avg +18.6% | Bloom Burton | $13.88 | Buy | −27.1% | Reiterated | 21.10.25on TipRanks Oct 22 12:30 | −0.3%next day −8.3% · 5 days −5.9% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Viridian Therapeutics
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $34.11 at a price of $20.59 (+65.7%); now: $34.11 at $19.03 (+79.2%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 28 | 28 | 17 | 15 | 8 | 8 |
| Buy | 4 | 4 | 3 | 4 | 4 | 4 |
| Hold | 3 | 2 | 1 | 1 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-1.02 (from $-1.26 to $-0.78). Last quarter: $-1.05.
Sales
Next quarter’s sales estimate — $5M (from $0M to $15M). Last quarter: $0M.
Best top-analyst consensus in the sector · Healthcare
About Viridian Therapeutics
- CEO: Stephen F. Mahoney
- Employees: 252
- 221 Crescent Street, Waltham, MA, 02453, US
- www.viridiantherapeutics.com
Viridian Therapeutics, Inc. is a biotechnology firm committed to creating therapies for patients afflicted by serious illnesses. Its primary development efforts include VRDN-001, a humanized monoclonal anti-IGF-1R antibody currently advancing through Phase 1/2 clinical trials for thyroid eye disease (TED). The company's portfolio also features VRDN-002, an IGF-1R antibody undergoing Phase 1 clinical evaluation, alongside VRDN-003, a therapeutic antibody also designed to target IGF-1R for TED. Established in 2006, this Waltham, Massachusetts-based firm previously operated as Miragen Therapeutics, Inc., before changing its name to Viridian Therapeutics, Inc. in January 2021.
Data from the stock’s TipRanks forecast page, read 66 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗